(Q40630612)

22 September 2017

title

Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children (English)

1 reference

22 September 2017

1 reference

1 reference

Castillo de Febres O

1

1 reference

22 September 2017

Chacon de Petrola M

2

1 reference

22 September 2017

Casanova de Escalona L

3

1 reference

22 September 2017

Naveda O

4

1 reference

22 September 2017

Naveda M

5

1 reference

22 September 2017

Estopinan M

6

1 reference

22 September 2017

Bordones G

7

1 reference

22 September 2017

Zambrano B

8

1 reference

22 September 2017

Garcia A

9

1 reference

22 September 2017

Dumas R

10

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

22 September 2017

number of pages

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

22 September 2017

volume

18

1 reference

22 September 2017

issue

7-8

1 reference

22 September 2017

page(s)

656-664

1 reference

Epidemiological patterns of hepatitis A in different parts of the world

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

An outbreak of hepatitis A in young adults in central Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Propagation of human hepatitis A virus in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Protection against hepatitis A by an inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Immunogenicity of inactivated hepatitis A vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Inactivated hepatitis A vaccine in childhood: implications for disease control

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Seroepidemiological investigation of patients and family contacts in an epidemic of hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Clinical development of a new inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Sensitive assays for hepatitis A antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Vaccination against hepatitis A virus in French hemophilic children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Persistence of vaccine-induced antibody to hepatitis A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Vaccination against hepatitis A: control 3 years after the first vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Persistence of vaccine-induced antibodies for hepatitis A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Six years' follow-up after hepatitis A vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

Response to Hepatitis A Vaccine in Children after a Single Dose with a Booster Administration 6 Months Later

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900272-8

7 January 2021

10.1016/S0264-410X(99)00272-8

Identifiers

DOI

1 reference

22 September 2017

1 reference